Fetal Lead Exposure at Each Stage of Pregnancy as a Predictor of Infant Mental Development by Hu, Howard et al.
 
Fetal Lead Exposure at Each Stage of Pregnancy as a Predictor of
Infant Mental Development
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Hu, Howard, Martha Mari-a Tellez-Rojo, David Bellinger, Donald
Smith, Adrienne S. Ettinger, Hector Lamadrid-Figueroa, Joel
Schwartz, Lourdes Schnaas, Adriana Mercado-Garci-a, and
Mauricio Hernandez-Avila. 2006. Fetal lead exposure at each
stage of pregnancy as a predictor of infant mental development.
Environmental Health Perspectives 114(11): 1730-1735.
Published Version doi:10.1289/ehp.9067
Accessed February 19, 2015 8:34:56 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:8157299
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA1730 VOLUME 114 | NUMBER 11 | November 2006 • Environmental Health Perspectives
Research | Children’s Health
The ﬁndings of a wide variety of international
studies on the impacts of lead exposure on
mental development persuaded many coun-
tries to progressively reduce the amount of lead
exposure deemed safe during childhood. Since
1991, the U.S. Centers for Disease Control
and Prevention (CDC) has recommended 10
µg/dL (0.48 µmol/L) as the pediatric blood
lead screening action guideline (CDC 1991),
with recent research (Canﬁeld et al. 2003) and
pooled analyses of seven prospective studies
(Lanphear et al. 2005) prompting considera-
tion of further reductions.
A related issue that has received less atten-
tion is the extent to which prenatal lead expo-
sure may produce adverse outcomes. This
issue has emerged as a potentially large public
health problem because of two recent insights.
First, substantial fetal lead exposure can occur
from mobilization of maternal skeletal lead
stores, which, in turn, can persist many years
after external lead exposure has declined
(Gulson et al. 2003; Hu and Hernandez-Avila
2002). Second is the growing appreciation of
the fetal nervous system’s exquisite sensitivity
to neurotoxins (Mendola et al. 2002). 
Until now, few epidemiologic studies have
used designs that allow the neurodevelopmen-
tal impacts of prenatal lead exposure to be dis-
tinguished from those of postnatal lead
exposure. Among these, some have shown an
inverse association between prenatal lead expo-
sure and infant neurodevelopment (Bellinger
et al. 1987; Dietrich et al. 1987; Ernhart et al.
1987; Shen et al. 1998) and some have not
(Cooney et al. 1989; McMichael et al. 1988).
Some found associations with neurodevelop-
ment that attenuated over subsequent years
(Bellinger et al. 1992; Dietrich et al. 1991;
Ernhart et al. 1987), whereas others found rela-
tions that were stable over time (Wasserman
et al. 1997, 2000).
An important factor that might contribute
to inconsistency across studies is variability in
the assessment and timing of dose to the fetus.
Some studies measured maternal whole blood
lead during the second and third trimesters and
at delivery (Baghurst et al. 1987; Schnaas et al.
2006), whereas others took measures in the ﬁrst
or second trimester (Dietrich et al. 1987), in
mid-pregnancy and at delivery (Wasserman
et al. 1997), or at delivery only (Cooney et al.
1989; Ernhart et al. 1986). Some studies relied
solely on umbilical cord blood lead level as the
index of prenatal exposure (Bellinger et al.
1987). One study measured perinatal maternal
bone lead level as an index of mobilizable
maternal lead burden during the course of
pregnancy (Gomaa et al. 2002).
The toxicokinetics of lead in the maternal–
fetal unit are poorly understood. Lead levels in
different compartments and at different stages
of pregnancy are only modestly correlated, sug-
gesting that each measure captures different
aspects of fetal exposure (Baghurst et al. 1987).
It is well known from the experimental litera-
ture that the vulnerability of developing organ
systems, including the brain, to environmental
toxicants can vary widely over the course of
pregnancy (Mendola et al. 2002). Thus, it is
plausible that lead exposure may be particu-
larly neurotoxic during a speciﬁc trimester. 
Recent evidence also suggests that whole
blood lead levels in a pregnant woman might
not be the optimal marker for lead concentra-
tions in the fetal brain. Over 99% of lead in
whole blood is bound to red cells and thus not
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BACKGROUND: The impact of prenatal lead exposure on neurodevelopment remains unclear in
terms of consistency, the trimester of greatest vulnerability, and the best method for estimating
fetal lead exposure. 
OBJECTIVE: We studied prenatal lead exposure’s impact on neurodevelopment using repeated meas-
ures of fetal dose as reﬂected by maternal whole blood and plasma lead levels.
METHODS: We measured lead in maternal plasma and whole blood during each trimester in 146
pregnant women in Mexico City. We then measured umbilical cord blood lead at delivery and,
when offspring were 12 and 24 months of age, measured blood lead and administered the Bayley
Scales of Infant Development. We used multivariate regression, adjusting for covariates and 24-
month blood lead, to compare the impacts of our pregnancy measures of fetal lead dose.
RESULTS: Maternal lead levels were moderately high with a ﬁrst-trimester blood lead mean (± SD)
value of 7.1 ± 5.1 µg/dL and 14% of values ≥ 10 µg/dL. Both maternal plasma and whole blood
lead during the ﬁrst trimester (but not in the second or third trimester) were signiﬁcant predictors
(p < 0.05) of poorer Mental Development Index (MDI) scores. In models combining all three
trimester measures and using standardized coefﬁcients, the effect of ﬁrst-trimester maternal plasma
lead was somewhat greater than the effect of ﬁrst-trimester maternal whole blood lead and substan-
tially greater than the effects of second- or third-trimester plasma lead, and values averaged over all
three trimesters. A 1-SD change in ﬁrst-trimester plasma lead was associated with a reduction in
MDI score of 3.5 points. Postnatal blood lead levels in the offspring were less strongly correlated
with MDI scores.
CONCLUSIONS: Fetal lead exposure has an adverse effect on neurodevelopment, with an effect that
may be most pronounced during the ﬁrst trimester and best captured by measuring lead in either
maternal plasma or whole blood.
KEY WORDS: bone, IQ, lead, plasma, pregnancy, neurodevelopment. Environ Health Perspect
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instead, it is the < 1% of lead in the plasma
compartment of blood that is of greatest inter-
est in terms of fetal exposure. Recent data sug-
gest that there are significant interindividual
differences in the ratio of red cell lead to
plasma lead (Hu 1998; Lamadrid-Figueroa
2006), making maternal whole blood lead lev-
els potentially unreliable as a proxy for plasma
lead and fetal exposure (Chuang et al. 2001;
Goyer 1990). 
To date, no study of fetal lead neurotoxicity
has included the biomarker measurements
needed to compare whole blood and plasma
lead levels during each trimester of pregnancy as
predictors of infant neurodevelopment. It is
such a comparison that we report here. 
Materials and Methods
Study subjects. Subjects were recruited between
May 1997 and July 1999 from 2,273 women
approached during prenatal visits at one of
three clinics of the Mexican Institute of Social
Security (IMSS) in Mexico City. Women were
eligible if they had a confirmed positive
β-human chorionic gonadotropin test or were
trying to become pregnant, lived in Mexico
City, and were willing to participate in the
3-year follow-up study protocol. Of the 2,273
women approached, 1,502 (66%) declined to
be enrolled. We applied the following exclu-
sion criteria to the 771 (34%) women who
were willing to participate (percent excluded in
parentheses): having plans to leave the area in
the following 5 years (3.7%); having a psychi-
atric disorder (0%); daily consumption of alco-
holic beverages (0%); addiction to illegal drugs
(0%); continuous use of prescription drugs
(0%); diagnosis of high-risk pregnancy
(10.9%), preeclampsia (0.9%), renal or circula-
tory disease including hypertension (8.4%), or
gestational diabetes (0.7%); suffering from
seizures that required medical treatment
(0.3%); and being pregnant with > 14 weeks of
gestation (15.3%). A total of 280 already preg-
nant women were recruited; 182 women with
a negative pregnancy test declared an intention
to become pregnant in the near future and
were also recruited. Of the latter group, 47
became pregnant, agreed to participate, and
were enrolled in the cohort comprising a total
of 327 pregnant women.
Of these 327 women, 216 continued the
full follow-up and bore children who were eval-
uated for the Bayley Mental Development
Index (MDI) (Bayley 1993) at 24 months of
age. Of these 216 mother–infant pairs, 146 met
the following inclusion criteria: child born with
at least 37 weeks of gestational age; at least one
valid measurement of plasma lead during any of
the three visits made during pregnancy; com-
plete information on maternal age and IQ; and
child’s blood lead level at 24 months of age, sex,
weight, and height. 
All mothers were informed about the
study; those who agreed to participate read
and signed a letter of informed consent. The
research protocol was approved by the Ethics
Committees of the National Institute of
Public Health of Mexico, the Harvard School
of Public Health, the Brigham and Women’s
Hospital, the University of California, and the
participating hospitals.
Blood and plasma lead measurement in
mothers. Blood and plasma samples were col-
lected during each prenatal visit of the mothers
to the Center for Environmental Health
Research of the American British Cowdray
(ABC) Hospital in Mexico City. Visits were
scheduled at 12, 24, and 34 weeks of preg-
nancy, and samples were classified as corre-
sponding to first, second, or third trimester
according to the timing of these visits. Subjects
were instructed to fast overnight before sample
collection. Before venipuncture, each subject’s
arm was washed with ultrapure water and disin-
fected with reagent-grade alcohol. Three milli-
liters of venous whole blood was collected with
a butterﬂy catheter (19 gauge) into a low-lead
container (Vacutainer B-D 367734; Becton-
Dickinson, Franklin Lakes, NJ, USA) for
blood lead analysis, and 13 cm3 venous blood
was then collected into a polyethylene tube
containing 100 ISP (international units)
sodium heparin (H-3393; Sigma Chemical
Company, St. Louis, MO, USA), processed,
and shipped to the trace metal facility at the
University of California, Santa Cruz, for meas-
urement of whole blood lead and plasma lead
using ultra-clean methods detailed elsewhere
(Hernandez-Avila et al. 1998; Smith et al.
1998). All samples were analyzed using induc-
tively coupled plasma mass spectrometry (ICP-
MS; Thermo Finnigan, Bremen, Germany).
Potential contamination by lead from hemo-
lyzed red cells was assessed by measuring levels
of plasma iron and free hemoglobin using sensi-
tive methods previously described in detail
(Smith et al. 1998). Accordingly, 18 samples
were determined to be contaminated and
excluded from further analyses. 
Children’s blood lead measurement.
Umbilical cord and infant venous blood sam-
ples at 24 months were collected in trace
metal–free tubes. Due to the logistical con-
straints posed by the collection of samples dur-
ing birth from multiple hospitals and at
unpredictable hours, we obtained data on cord
blood on only 57% of the mothers participat-
ing in this study. Samples were analyzed for
lead using an atomic absorption spectrometry
(AAS) instrument (model 3000; PerkinElmer,
Chelmsford, MA, USA) at the metals labora-
tory of the ABC Hospital, which participates
in the external validation protocol of the
Wisconsin Laboratory of Hygiene. The
Pearson correlation coefficient between all
available measurements by AAS and those by
ICP-MS was 0.93 (in mothers). Precision was
similar using either measuring technique; stan-
dard deviations were not signiﬁcantly different
(p = 0.32); and accuracy was comparable (with
difference in means < 1.0 µg/dL). 
Measurement of child development and
potential confounders. Infant development at
24 months was assessed by trained personnel
using the Bayley Scales of Infant Development
II–Spanish version (BSID-IIS) (Bayley 1993)
using a standardized protocol described in a
previous study by our research group (Gomaa
et al. 2002). All assessors were blind to the
children’s in utero and postnatal lead measure-
ments. MDI scores at 24 months of age were
considered the primary outcome. Information
on demographic, socioeconomic, and other
factors that could confound the relationship
between lead and child development was col-
lected. Maternal IQ was assessed using the
Information, Comprehension, Similarities,
and Block Design subtests of the Wechsler
Adult Intelligence Score (Wechsler 1968).
Statistical analysis. Descriptive statistics
and appropriate transformations were per-
formed before bivariate analyses. Outliers were
identiﬁed using the ESD (Extreme Studentized
Deviate) Many-Outlier procedure (Rosner
1983). We calculated Spearman correlation
coefficients among the lead measurements.
Height and weight data were transformed into
Z-scores by using World Health Organization
(WHO)/National Center for Health Statistics/
CDC reference data (WHO 1979) and inter-
preted as indices of a child’s nutritional status.
Variables considered to be potential con-
founders based on biologic plausibility, regard-
less of statistical significance, and those
significantly (p < 0.1) associated with MDI
scores in bivariate analyses were included in
multiple linear regression models; given these
criteria, confounders included were child’s sex,
blood lead at 24 months of age, height for age
z-score and weight, as well as maternal age and
intelligence quotient. All models featured loge-
transformed lead measures because this proce-
dure provided the best ﬁt. We ﬁrst generated
“single-trimester” models, in which we evalu-
ated the associations between MDI score and
loge-transformed plasma and whole blood lead
levels during each trimester of pregnancy
adjusting for potential confounders. We gener-
ated “multitrimester” models, incorporating, in
each model, the data from either plasma or
whole blood lead concentrations from all three
trimesters. We also ran models using maternal
plasma lead or whole blood lead, averaged over
all three trimesters.
To enable better comparability of the rela-
tive effects of plasma lead and blood lead, we
compared effect estimates for a 1-SD change in
each exposure metric. We carried out a similar
analysis using loge-transformed cord blood lead
levels as a proxy variable for prenatal lead
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exposure to lead in postnatal life, we also mod-
eled MDI as a function of the child’s blood
lead concentrations at 24 months of age. 
Due to postponed visits to the research cen-
ter visits of some women, misclassiﬁcation of
the timing of some of the visits occurred (e.g., a
visit intended for the ﬁrst trimester occurred
during the second trimester; see Figure 1 for
graphic display of misclassiﬁcation). To account
for the potential bias in results, we repeated the
“intention to treat” analyses presented in this
article, including only those observations that
were correctly classiﬁed as corresponding to the
ﬁrst, second, and third trimesters of pregnancy
according to actual gestational age. 
Regression diagnostics were performed on
all models to evaluate multicollinearity, distrib-
utional assumptions on the error term, and
potentially inﬂuential data points. When the
latter were detected, we ﬁt new models exclud-
ing these observations. All statistical analyses
were performed using STATA (STATA
Statistical Software, release 8.0; StataCorp,
College Station, TX, USA).
Results
In the 146 mother–infant pairs in our final
study group, no differences significantly
greater than zero were noted in maternal age,
number of years in school, IQ, and children’s
hemoglobin, height, weight, and MDI when
compared with mother–child pairs who par-
ticipated but who did not meet the inclusion
criteria for this analysis (n = 70; data not
shown). Circulating levels of lead in the
included mothers were moderately high, with
mean (± SD) values for first-trimester whole
blood lead of 70.7 ± 51.0 µg/L and 14% of
values ≥ 10 µg/L (Table 1). (Whole blood lead
values are expressed in this article as micro-
grams per liter for ease of comparison with
plasma levels.) Both maternal plasma and
whole blood lead followed a U-shaped pattern
over the course of pregnancy, reaching their
lowest points during the second trimester and
rising during the third trimester. 
As expected, measurements of lead bio-
markers in the three stages of pregnancy were
moderately well correlated (all p < 0.05);
Spearman correlations between blood lead
measurements at different stages of pregnancy
(mean = 0.72; range, 0.67–0.81) were, on aver-
age, higher than their plasma lead counterparts
(mean = 0.62; range, 0.55–0.69). Cord blood
lead was most highly correlated with maternal
whole blood lead measured during the third
trimester of pregnancy (r = 0.5436, p < 0.001).
Cord blood lead concentrations were 10.6
µg/L lower, on average, than maternal whole
blood lead levels at delivery. Children’s whole
blood lead levels at 12 and 24 months of age
were correlated (r = 0.58, p < 0.01) and lower,
on average, than their cord blood lead levels.
Hu et al.
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Table 1. Characteristics of the study population of mother–infant pairs.
Characteristics No. Mean ± SD Range
Mothers
Age (years) 146 27.1 ± 5.3 15–43
IQ 146 89.1 ± 12.9 55–120
Whole blood lead (µg/L)
First trimester 119 70.7 ± 51.0 14.9–435.9
Second trimester 136 60.8 ± 31.5 15.8–224.4
Third trimester 132 68.6 ± 42.3 15.3–330.8
Delivery 111 72.6 ± 43.3 15–324
Plasma lead (µg/L)
First trimester 119 0.16 ± 0.14 0.04–0.99
Second trimester 136 0.14 ± 0.11 0.03–0.67
Third trimester 132 0.16 ± 0.24 0.03–2.63
Children
Birth weight (g) 146 3,144 ± 359 2,125–4,000
Male sex (%) 76 52.05
Blood lead (µg/L)
Cord 83 62.0 ± 38.8 9–200
12 months 125 52.2 ± 34.1 9–204
24 months 146 47.9 ± 37.1 8–368
Height at 24 months (cm) 146 86.1 ± 3.0 74–93
Weight at 24 months (kg) 146 11.98 ± 1.55 9.4–19.3
Hemoglobin (g/dL)  135 12.4 ± 1.2 7.1–14.8
MDI score (at 24 months) 146 91.5 ± 11.6 68–122
Figure 1. Plasma lead levels during pregnancy according to gestational age. Plasma lead measurements
were taken at what were intended to be the ﬁrst, second, and third trimesters. Dotted lines mark the 13th
and 26th weeks of gestation.
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Table 2. Single-trimester multivariate linear regression models for MDI of offspring (at 24 months of age)
comparing markers of lead exposure at different times for blood lead and plasma lead. 
Variable No. β p-Value 95% CI
Pregnancy
Blood lead (µg/L)
First trimester 119 –4.13 0.04 –8.10 to –0.17
Second trimester 136 –4.08 0.06 –8.29 to 0.12
Third trimester 132 –2.42 0.23 –6.38 to 1.54
Averagea 146 –3.52 0.10 –7.66 to 0.63
Plasma lead (µg/L)
First trimester 119 –3.77 0.03 –7.12 to –0.42
Second trimester 136 –2.48 0.13 –5.74 to 0.77
Third trimester 132 –0.32 0.83 –3.38 to 2.74
Averagea 146 –3.11 0.07 –6.53 to 0.31
Delivery
Cord blood lead (µg/L)  83 –0.35 0.88 –4.72 to 4.03
Postnatal
Child blood lead (µg/L) 
12 months 125 –2.38 0.23 –6.24 to 1.49
24 months 146 –1.00 0.50 –3.93 to 1.94
CI, conﬁdence interval. Each model is adjusted for infant’s concurrent blood lead (24 months of age), sex, maternal age,
current weight, height-for-age Z-score, and maternal IQ. Logarithmically transformed lead concentrations were used.
Each line in the table represents a different model. 
aThe arithmetic mean of log-blood lead or log-plasma lead using all available measurements. Single-trimester models of MDI scores
(Table 2) suggested a negative relationship
between circulating lead in each trimester of
pregnancy and MDI scores at 24 months of
age, adjusting for maternal age and IQ and
child’s concurrent blood lead, sex, weight and
height-for-age Z-score. MDI was most strongly
associated with lead concentrations during the
first trimester for both plasma (standardized
coefﬁcient, –4.13; p = 0.03) and whole blood
lead (standardized coefﬁcient, –3.77; p = 0.04).
Both maternal plasma and whole blood lead
averaged over all three trimesters had associa-
tions with MDI of borderline significance
(standardized coefﬁcients of –3.52, p = 0.07;
and –3.11, p = –0.10, respectively).
When we repeated the analysis using only
those measurements correctly classified in
each trimester of pregnancy, we found that
lead concentrations during the ﬁrst trimester
were signiﬁcantly associated with a decrease in
MDI at 24 months of age. The estimated
coefﬁcients in the ﬁrst trimester (n = 56) were
–6.39 (p = 0.04) and –6.94 (p = 0.04) points
per log micrograms per liter of plasma and
whole blood lead, respectively. The coeffi-
cients for the second trimester plasma and
whole blood lead levels (n = 102) were much
smaller (–1.73, p = 0.38; and –3.66, p = 0.16,
respectively). Umbilical cord lead at birth and
infant whole blood lead at 12 and 24 months
were inversely but weakly (p > 0.20) associ-
ated with MDI at 24 months. 
In multitrimester models (Table 3), the
plasma lead model predicts that an increase of 1
SD in loge-transformed plasma lead in the ﬁrst
trimester is associated with a 3.5-point lower
MDI score at 24 months of age (p = 0.03). The
corresponding increase in whole blood lead
during the first trimester is associated with a
2.4-point lower MDI score at 24 months of age
(p = 0.19). When first-trimester plasma lead
concentrations were included in the model,
plasma lead concentrations in the second and
third trimester were not signiﬁcantly associated
with MDI. When both plasma and whole
blood lead are simultaneously evaluated,
although none of the standardized coefﬁcients
are statistically signiﬁcant, the plasma lead coef-
ﬁcient is more than twice as great as its blood
lead counterpart (–1.68, p = 0.36; and –0.77,
p = 0.68, respectively).
The logarithmic nature of the relationship
between ﬁrst-trimester plasma lead levels and
MDI at 24 months of age is depicted in Figure
2. The vertical line represents the mean plasma
lead (0.24 µg/L) corresponding to a whole
blood lead concentration of 10 µg/L. The slope
is steeper at lower levels. Linear regression
models of the association using nontrans-
formed plasma lead had a similar pattern.
When the model is restricted to plasma lead
observations below the median (0.1226 µg/L),
an increase of 0.1 µg/L in plasma lead in the
first trimester is associated with a 15-point
decline in MDI score at 24 months of age, in
contrast to a 4-point decline per 0.1-µg/L
increase in plasma lead for observations above
the median plasma lead—conﬁrming that the
nonlinear pattern is not an artifact of our trans-
formation of the variable.
Discussion
This study is the ﬁrst of which we are aware
that attempted to compare the relative inﬂu-
ence on neurodevelopmental toxicity of two
different biomarkers of fetal lead exposure at
each stage of pregnancy. We found that both
maternal blood lead and maternal plasma lead
vary considerably over pregnancy; first-
trimester levels of either measures were better
than second- or third-trimester levels or levels
averaged over all three trimesters at predicting
infant neurobehavioral performance at age
24 months; and ﬁrst-trimester maternal plasma
lead levels were somewhat better than first-
trimester maternal whole blood lead levels at
predicting infant neurobehavioral performance
at 24 months of age. 
Our study had several limitations. Our
sample size was modest, a reflection of the
labor- and cost-intensive nature of collecting
plasma samples using a rigorous protocol.
Nevertheless, we were able to successfully dis-
tinguish and compare the relative contribu-
tions to neurodevelopment of trimester- and
biomarker-speciﬁc measures of exposure. Our
subjects were a small subset of women who
had been initially approached in the clinics
(n = 2,273), raising the issue of the generaliz-
ability of our study. However, the women
included in our ﬁnal sample did not differ sig-
niﬁcantly from other eligible subjects on key
covariates, suggesting that our sample was quite
Fetal lead exposure and infant mental development 
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Table 3. Multivariate models of MDI of offspring (at 24 months of age) using either whole blood or plasma
lead concentrations as markers of prenatal lead exposure at different trimesters of pregnancy. 
Plasma model (R2 = 0.22) Blood model (R2 = 0.21)
Variable β p-Value β p-Value
Pb ﬁrst trimestera –3.54 0.03 –2.40 0.19
Pb second trimestera 0.80 0.65 –1.29 0.56
Pb third trimestera 1.18 0.44 1.42 0.46
Current blood leadb –0.01 0.62 –0.01 0.80
Sexc 3.64 0.13 3.50 0.15
Height-for-age Z-score 2.87 0.05 2.71 0.06
Current weight (kg) –1.70 0.06 –2.00 0.02
Mother’s IQ 0.08 0.40 0.08 0.39
Mother’s age (years) 0.59 0.01 0.62 0.01
Intercept 84.25 < 0.01 87.18 < 0.01
These are the results of two multivariate regression models with either plasma lead or whole blood concentrations in dif-
ferent trimesters of pregnancy simultaneously included in each of the two models. Coefﬁcients are mean change in MDI
per increase of 1 SD in loge lead concentrations, which allows for direct comparisons between the beta-coefﬁcients of
plasma lead versus blood lead.
aPlasma lead concentration (µg/L) in corresponding trimester. bInfant whole blood lead (µg/L) at 24 months of age. cInfant
sex: 1 = male, 2 = female.
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Figure 2. Plasma lead levels in the ﬁrst trimester of pregnancy versus MDI scores at 24 months of age. CI,
conﬁdence interval. Curve indicates the best-ﬁt model for the association between plasma lead levels and
MDI scores, adjusting for plasma lead levels in the second and third trimesters, mother’s age and IQ,
child’s blood lead levels at 24 months of age, sex and height-for-age Z-score. Vertical line marks average
plasma lead concentration when whole blood lead equals 100 µg/L.representative of the women serviced by our
participating clinics. Some of our observations
were misclassified with respect to trimester;
however, our results were very similar in the
reanalysis using classification corrections.
Indeed, the association between ﬁrst-trimester
lead exposure and infant neurodevelopment
appeared to be even greater, a ﬁnding that sug-
gests that there was downward bias due to
improper assignment of second-trimester
women to the ﬁrst trimester category. We did
not control for a summary measure of home
conditions, such as the Home Observation for
Measurement of the Environment (HOME)
score; however, the absence of this covariate is
unlikely to explain differences in effects
among the three trimesters of lead exposure.
Finally, offspring blood lead levels at 24
months did not significantly predict lower
MDI score; on the other hand, our sample
size, again, was modest, and in a separate
analysis of the larger group of mother–infant
pairs participating in this research (n = 294)
that was not confined to women who had
plasma lead measurements, we found a signiﬁ-
cant adverse impact of offspring blood lead
levels at 24 months of age on 24-month MDI
score (Tellez-Rojo et al. 2006). 
The best-fitting model relating first-
trimester plasma lead to 24-month MDI scores
was one in which lead level was expressed as
the natural logarithm of the measured value.
This suggests that the shape of the dose–effect
relationship is supralinear, with a steeper slope
at lower plasma lead levels. This is consistent
with the blood lead–IQ relationships in chil-
dren reported by Canfield et al. (2003), in
reanalyses of the Boston prospective study of
children (Bellinger and Needleman 2003), and
in pooled analyses that included several addi-
tional prospective studies (Lanphear et al.
2005). In quantitative terms, however, the
rates of change over both ranges of plasma lead
level were approximately twice as great as those
reported by Canﬁeld et al. (2003). Meta-analy-
ses of multiple studies have converged on an
estimate of a 2–3 IQ point decrement for each
10-µg/dL increase in postnatal blood lead level
(International Program on Chemical Safety
1995; Pocock et al. 1994; Schwartz 1994), but
these estimates might reﬂect mostly the region
of the dose–effect relationship in which the
slope is shallower. Moreover, blood lead is a
surrogate measured with error for toxicologi-
cally available lead, and the larger effect size
estimates for plasma lead suggest that many
previous studies may have had effect estimates
downwardly biased by measurement error. 
We are not aware of previous studies for
comparison that have included maternal meas-
ures of circulating lead at each stage of preg-
nancy. Although Schnaas et al. (2006) also
studied lead exposure and neurobehavior in a
cohort of Mexico City children from the
in utero period to childhood (and found a
significant adverse impact of in utero lead
exposure), their observations began after the
12th week of pregnancy and thus precluded
examination of the direct effects of first-
trimester lead exposure. 
In experimental studies, lead is known to
affect a wide range of processes critical to cen-
tral nervous system development, including dif-
ferentiation (Alfano and Petit 1982; Petit and
LeBoutillier 1979; Petit et al. 1983), myelina-
tion (Mendola et al. 2002), and synaptogenesis
(Johnston and Goldstein 1998). Of these, dif-
ferentiation is primarily a ﬁrst-trimester event,
making a targeting of this process as a possible
explanation for our ﬁnding of a ﬁrst-trimester
dominant effect. 
Mobilization of maternal bone lead stores
has been clearly identiﬁed as a major source of
fetal lead exposure (Gulson et al. 2003; Hu
and Hernandez-Avila 2002), and elevated
maternal bone lead stores can be expected in
women with ongoing environmental or occu-
pational exposures and in women who have
retained bone lead burdens from earlier lead
exposures. The women in our study fell into
the latter category, having lived in Mexico
City, where leaded gasoline was combusted
until 1997. Some have suggested that fetal lead
exposure resulting from the mobilization of
maternal bone lead stores during pregnancy
can be reduced by calcium supplementation
(Gulson et al. 2004; Janakiraman et al. 2003).
Our study suggests that if such a strategy were
to prove useful in reducing lead exposure to
the fetus, it would have to be implemented
very early in pregnancy to maximize the beneﬁt
to fetal neurodevelopment. 
Our ﬁndings do not mean that measure-
ment of maternal plasma lead is likely to
become a clinically useful environmental
health tool. The methods required to measure
plasma lead are laborious and require special
and expensive equipment. However, this bio-
marker is a useful research tool in efforts to
understand and detect the health impacts of
environmental lead exposure. 
In conclusion, we found that ﬁrst-trimester
measures of fetal lead exposure—particularly
levels of lead in maternal plasma, but also levels
of lead in maternal whole blood—were predic-
tive of adverse neurodevelopment later in life,
with an effect that was independent from that
of postnatal lead exposure and that was stronger
than the effects associated with second- or
third-trimester measures. This is of major
potential public health concern because lead
remains a widespread environmental health
hazard and current efforts at primary preven-
tion have focused almost entirely on childhood
rather than fetal exposure. If future research
conﬁrms this ﬁnding, ascertaining women at
risk and identifying effective strategies for pre-
vention of fetal lead exposure may become an
important public health priority; moreover, it
may be necessary to consider prepregnancy
interventions, because our research suggests that
screening and intervention any later than the
ﬁrst trimester may be too late to prevent the
greatest fetal neurotoxic effects. 
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